Flash Finance

IPCA Laboratories LimitedIPCALABCorporate

Healthcare Drug Manufacturers - Specialty & Generic Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹1,832.60
MCap ₹46,494 Cr · P/E 33.7
IPCA Laboratories Limited — Stock analysis & AI research IPCA Laboratories Limited — Seasonality — best & worst months IPCA Laboratories Limited — Technical indicators & charts IPCA Laboratories Limited — Technical setup — score, trend, support & resistance IPCA Laboratories Limited — Ascending Channel pattern forming IPCA Laboratories Limited — Live exchange announcements
📋 High Interest Coverage Stocks📋 High Profit Growth Stocks📋 Stocks With Strong Quarterly Results📋 GARP Stocks (PEG Below 1)📋 Low Debt Stocks📋 Mid Cap Stocks List 📈 SuperTrend Bearish Signal📈 20-Day Breakdown Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹2,788 Cr
Sales · Jun 2026
+20.8% YoY
₹670 Cr
Operating Profit · Jun 2026
+60.8% YoY
24.0%
OPM % · Jun 2026
+33.3% YoY
₹424 Cr
Net Profit · Jun 2026
+82.2% YoY
₹15.84
EPS · Jun 2026
+72.4% YoY

📝 IPCA Laboratories Limited — results explained

Quarter ended June 2026 (Q1 FY27)

IPCA Laboratories Limited reported revenue of ₹2,788 crore for the quarter ended June 2026 (Q1 FY27), up 20.8% from ₹2,309 crore in the same quarter last year, and up 16.8% sequentially over the March 2026 quarter.

Net profit rose 82.2% year-on-year to ₹424 crore, from ₹233 crore. Earnings per share (EPS) came in at ₹15.84.

Operating profit stood at ₹670 crore — an operating margin (OPM) of 24.0%, compared with 18.0% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, IPCA Laboratories Limited posted revenue of ₹9,645 crore, a growth of 7.9% over FY25, with a net profit of ₹1,187 crore (up 55.0% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹10,125 crore with a net profit of ₹1,379 crore.

Valuation snapshot

At the current price of ₹1,832.60, IPCALAB has a market capitalisation of ₹46,494 crore and a trailing P/E of about 33.7.

Within the Drug Manufacturers - Specialty & Generic industry, it is the 14th-largest of the 31 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 44.72%, foreign institutional investors (FIIs) 11.53%, domestic institutional investors (DIIs) 36.59%, public shareholders 7.15% of IPCA Laboratories Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹46,494 Cr
Current Price ?
₹1,832.6
P/E ?
33.72below ind
Industry P/E ?
35.00
P/B ?
5.77
P/S ?
4.59
P/FCF ?
56.36
Enterprise Value ?
₹47,303 Cr
EV/EBITDA ?
21.20
PEG ?
0.89
Earnings Yield ?
3.8%
Dividend Yield ?
0.21%
Profitability & Returns
Sales (TTM) ?
₹10,125 Cr
OPM ?
22.0%
Profit after tax (TTM) ?
₹1,379 Cr
EPS (TTM) ?
₹54.35
ROCE ?
17.0%
ROE ?
17.1%
ROA ?
11.1%
Growth
Sales — latest qtr ?
₹2,788 Cr
PAT — latest qtr ?
₹424 Cr
YoY qtr sales growth ?
20.8%
YoY qtr profit growth ?
82.2%
Sales growth (3y) ?
16%
Sales growth (5y) ?
12%
Profit growth (3y) ?
38%
Profit growth (5y) ?
1%
Financial Health
Debt ?
₹809 Cr
Debt to Equity ?
0.10
Interest Coverage ?
20.5
Current Ratio ?
N/A
Ownership
Promoter holding ?
44.72%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
-3.6%
Return 6 months ?
24.8%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 1,5461,5121,5882,0342,0532,0332,0932,3552,2452,2472,3092,5562,3922,3882,788 +20.8% +16.8%
Operating Profit 216181308321331305393441463410416545533484670 +60.8% +38.3%
Other Income 31364539222212620453328384825 -22.7% -47.4%
Interest 111831443329242317221920182012 -35.8% -40.6%
Depreciation 67706990100989910098100100103108107111 +10.7% +3.6%
Profit Before Tax 16912925222528977290345368128331392446404572 +73.1% +41.6%
Net Profit 110781641361806019222927668233284364307424 +82.2% +38.2%
EPS 4.253.026.425.727.092.357.589.059.782.679.1911.1412.8611.7915.84 +72.4% +34.4%
OPM % 14.0% 12.0% 19.4% 15.8% 16.1% 15.0% 18.8% 18.7% 20.6% 18.2% 18.0% 21.3% 22.3% 20.3% 24.0% +33.3% +18.2%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹8,940 Cr ₹9,645 Cr ₹10,125 Cr +7.9%
Operating Profit ₹1,707 Cr ₹1,978 Cr ₹2,231 Cr +15.9%
OPM % 19.10% 20.51% 22.04% +7.4%
NPM % 8.57% 12.31% 13.62% +43.6%
Other Income ₹112 Cr ₹147 Cr ₹139 Cr +30.9%
Depreciation ₹398 Cr ₹418 Cr ₹429 Cr +5.2%
Interest ₹85 Cr ₹76 Cr ₹69 Cr -10.4%
EBIT ₹1,309 Cr ₹1,560 Cr ₹1,802 Cr +19.2%
PBT ₹1,131 Cr ₹1,572 Cr ₹1,814 Cr +39.0%
Tax ₹344 Cr ₹204 Cr ₹257 Cr -40.6%
Net Profit ₹766 Cr ₹1,187 Cr ₹1,379 Cr +55.0%
EPS ₹29.08 ₹44.98 ₹51.63 +54.7%
Material Cost ₹1,335 Cr ₹1,441 Cr ₹1,476 Cr +7.9%
Employee Cost ₹973 Cr ₹1,081 Cr ₹1,140 Cr +11.1%
Extraordinary Items ₹-205 Cr ₹58 Cr ₹58 Cr +128.4%

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 25252525 +0.0%
Reserves 5,8176,3076,9238,038 +16.1%
Borrowings 1,4811,4381,363809 -40.6%
Other Liabilities 1,3003,3263,4323,498 +1.9%
Total Liabilities 8,62311,09711,74412,370 +5.3%
Fixed Assets 2,7514,5544,2674,638 +8.7%
CWIP 140343622762 +22.5%
Investments 626862980844 -13.9%
Other Assets 5,1055,3395,8756,127 +4.3%
Total Assets 8,62311,09711,74412,370 +5.3%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 8069451,3211,142 -13.6%
Cash from Investing Activity -725-1,215-870-247 +71.6%
Cash from Financing Activity 507-553-283-754 -166.4%
Net Cash Flow 588-823169142 -16.0%
Free Cash Flow 347543551825 +49.7%
CFO/OP 110%94%97%79% -18.6%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 58807776 -1.3%
Inventory Days 276350336353 +5.1%
Days Payable 83110111122 +9.9%
Cash Conversion Cycle 251321302308 +2.0%
Working Capital Days 71111101133 +31.7%
ROCE % 11%13%15%17% +13.3%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026 % Chg
Promoters 44.72%44.72%44.72%44.72%44.72% +0.0%
FIIs 10.67%10.42%10.62%10.63%11.53% +8.5%
DIIs 35.88%36.45%36.99%37.13%36.59% -1.5%
Government 0.32%0.32%0.32%0.32%— —
Public 8.41%8.09%7.33%7.21%7.15% -0.8%
No. of Shareholders 85,58282,87077,67382,18490,514 +10.1%

⚖️ Peer comparison

Industry: Drug Manufacturers - Specialty & Generic · top 25 of 31 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUNPHARMA Sun Pharmaceutical ₹1,840.00 441,478 36.5 59,911 12,104 29.8% 20.2% 11.2% 5.1% 10.5% 27.0%
2 DIVISLAB Divi's Laboratories ₹9,235.00 245,160 83.8 11,230 2,925 35.3% 26.0% 12.8% 16.7% 27.8% 65.5%
3 TORNTPHARM Torrent Pharmaceuticals ₹4,931.00 187,559 87.1 15,723 2,156 33.0% 13.7% 21.4% 11.9% 54.8% 3.3%
4 ZYDUSLIFE Zydus Lifesciences ₹1,162.20 115,930 23.2 27,148 5,070 31.2% 18.7% 16.8% 12.0% 16.2% 14.5%
5 CIPLA Cipla ₹1,366.00 110,353 32.7 28,324 3,356 18.7% 11.8% 2.2% -26.7% 2.3% -39.2%
6 LAURUSLABS Laurus Labs ₹1,969.00 106,387 97.2 7,270 1,090 28.0% 15.0% 22.7% 147.9% 29.1% 123.9%
7 DRREDDY Dr. Reddy's ₹1,165.50 97,085 29.3 28,704 3,273 15.3% 11.4% -10.4% -25.8% -5.6% -69.2%
8 AUROPHARMA Aurobindo Pharma ₹1,679.80 96,652 26.2 34,935 3,711 20.3% 10.6% 6.1% 0.6% 16.3% 25.2%
9 LUPIN Lupin ₹2,095.00 95,797 17.9 27,958 5,356 31.5% 19.2% 23.1% 62.0% 31.9% 87.8%
10 MANKIND Mankind Pharma ₹2,280.00 94,174 46.1 14,738 2,067 26.0% 14.0% 16.3% -3.7% 12.9% 29.1%
11 GLENMARK Glenmark Pharmaceuticals ₹2,419.20 68,276 38.0 17,737 1,797 27.0% 10.1% -61.2% -67.4% 23.1% 927.9%
12 ALKEM Alkem Laboratories ₹5,243.50 62,694 29.1 15,081 2,187 20.1% 14.5% 13.5% 7.6% 10.9% -21.6%
13 ABBOTINDIA Abbott India ₹25,860.00 54,951 34.0 7,005 1,615 28.1% 23.1% 8.1% 9.7% 4.4% 17.2%
14 IPCALAB Ipca Laboratories ₹1,964.20 49,833 38.0 10,125 1,379 22.0% 13.6% 7.9% 55.0% 20.8% 82.2%
15 GLAND Gland Pharma ₹2,935.90 48,433 47.1 6,431 1,028 25.3% 16.0% -64.7% -48.4% 22.3% 96.7%
16 AJANTPHARM Ajanta Pharma ₹3,398.90 42,472 37.4 5,777 1,135 25.4% 19.7% 17.3% 14.8% 24.8% 30.9%
17 JBCHEPHARM J. B. ₹2,416.10 38,793 53.4 4,148 709 26.7% 17.1% 5.9% 7.5% -4.8% -30.7%
18 EMCURE EMCURE PHARMACEUTICALS ₹1,975.10 37,470 37.0 9,684 1,019 20.4% 10.5% 16.6% 33.1% 22.8% 36.0%
19 WOCKPHARMA Wockhardt ₹2,021.50 32,848 92.5 3,133 353 19.9% 11.3% -2.3% 342.1% 25.9% 199.1%
20 NEULANDLAB Neuland Laboratories ₹23,455.00 30,093 82.7 2,023 365 28.4% 18.0% 37.0% 40.2% 136.3% 666.0%
21 PPLPHARMA Piramal Pharma ₹211.50 28,024 113.5 9,206 247 11.0% 2.7% -3.1% -37.9% 17.4% -161.3%
22 GRANULES Granules India ₹885.60 21,945 32.8 5,633 663 22.7% 11.8% 19.7% 18.8% 22.0% 59.3%
23 CAPLIPOINT Caplin Point ₹2,752.60 20,923 31.4 2,287 678 34.8% 29.7% 12.9% 20.2% 19.6% 18.8%
24 ERIS Eris Lifesciences ₹1,358.00 18,820 29.0 3,230 666 35.2% 20.6% 8.2% 72.6% 13.0% 14.6%
25 ASTRAZEN AstraZeneca Pharma ₹6,755.00 16,888 99.6 2,432 170 9.4% 7.0% 32.7% 62.1% 29.7% -32.1%
❓ Frequently asked questions
What was IPCA Laboratories Limited's revenue in Q1 FY27?
IPCA Laboratories Limited reported revenue of ₹2,788 crore for the quarter ended June 2026 (Q1 FY27), up 20.8% from ₹2,309 crore in the same quarter last year, and up 16.8% sequentially over the March 2026 quarter.
What was IPCA Laboratories Limited's net profit in Q1 FY27?
Net profit rose 82.2% year-on-year to ₹424 crore, from ₹233 crore. Earnings per share (EPS) came in at ₹15.84.
What is IPCALAB's market capitalisation and P/E ratio?
At the current price of ₹1,832.60, IPCALAB has a market capitalisation of ₹46,494 crore and a trailing P/E of about 33.7.
Who owns IPCA Laboratories Limited? (shareholding pattern)
As of Sep 2026, promoters held 44.72%, foreign institutional investors (FIIs) 11.53%, domestic institutional investors (DIIs) 36.59%, public shareholders 7.15% of IPCA Laboratories Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI